Literature DB >> 19896708

miR-138 might reverse multidrug resistance of leukemia cells.

Xiaohong Zhao1, Li Yang, Jianguo Hu, Jigang Ruan.   

Abstract

Here we firstly investigated the role of miR-138 in multidrug resistance of leukemia cells. miR-138 was found up-regulated in the vincristine-induced multidrug resistance (MDR) leukemia cell line HL-60/VCR as compared with HL-60 cells. Up-regulation of miR-138 could reverse resistance of both P-glycoprotein-related and P-glycoprotein-non-related drugs on HL-60/VCR cells, and promote adriamycin-induced apoptosis, accompanied by increased accumulation and decreased releasing amount of adriamycin. miR-138 could significantly down-regulate the expression of P-glycoprotein, Bcl-2, and the transcription of the multidrug resistance gene 1. Further study of the biological functions of miR-138 might be helpful for developing possible strategies to treat leukemia. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19896708     DOI： 10.1016/j.leukres.2009.10.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  48 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  Identification and experimental validation of G protein alpha inhibiting activity polypeptide 2 (GNAI2) as a microRNA-138 target in tongue squamous cell carcinoma.

Authors:  Lu Jiang; Yang Dai; Xiqiang Liu; Cheng Wang; Anxun Wang; Zujian Chen; Caroline E Heidbreder; Antonia Kolokythas; Xiaofeng Zhou
Journal:  Hum Genet       Date:  2010-11-16       Impact factor: 4.132

3.  miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics.

Authors:  Khalid Sossey-Alaoui; Edward F Plow
Journal:  Mol Cancer Res       Date:  2015-10-16       Impact factor: 5.852

Review 4.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

5.  The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.

Authors:  Taryn E Dick; Jeremy A Hengst; Todd E Fox; Ashley L Colledge; Vijay P Kale; Shen-Shu Sung; Arun Sharma; Shantu Amin; Thomas P Loughran; Mark Kester; Hong-Gang Wang; Jong K Yun
Journal:  J Pharmacol Exp Ther       Date:  2015-01-06       Impact factor: 4.030

Review 6.  MicroRNAs and their relevance to ABC transporters.

Authors:  Sierk Haenisch; Anneke Nina Werk; Ingolf Cascorbi
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

Review 7.  Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia.

Authors:  Yan Liu; Zhiheng Cheng; Yifan Pang; Longzhen Cui; Tingting Qian; Liang Quan; Hongyou Zhao; Jinlong Shi; Xiaoyan Ke; Lin Fu
Journal:  J Hematol Oncol       Date:  2019-05-24       Impact factor: 17.388

8.  Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 in vitro and in vivo.

Authors:  Jie Peng; Fang Hou; Jun Feng; Shui-Xian Xu; Xiao-Yan Meng
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

9.  Role of miR-138 in the regulation of larynx carcinoma cell metastases.

Authors:  Shang Gao; Jie Wang; Jin Xie; Tianzhen Zhang; Pin Dong
Journal:  Tumour Biol       Date:  2015-10-24

Review 10.  Role of microRNA-138 as a potential tumor suppressor in head and neck squamous cell carcinoma.

Authors:  Yi Jin; Dan Chen; Robert J Cabay; Anxun Wang; David L Crowe; Xiaofeng Zhou
Journal:  Int Rev Cell Mol Biol       Date:  2013       Impact factor: 6.813
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.